EXKIVITY™ available from Onco360!
EXKIVITY™ (mobocertinib) is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Dosage Form and Strength1
EXKIVITY is available as 40 mg capsules in 120-count pill bottles (NDC 63020-040-12).
Dosage and Administration
The recommended dose of EXKIVITY is 160 mg (4 capsules) orally once daily with or without food.
For complete details, visit Exkivity
How to Refer
Oncomed Dba Onco360 or
1EXKIVITY™ Prescribing Information: Takeda Pharmaceuticals America, Inc. EXKIVITY.com accessed 9/21. EXKIVITY™ is a trademark of Takeda Pharmaceuticals International AG.